LINFOCITOS Th-17 y PSORIASIS

DIANA V. RONDÓN
RESIDENTE PRIMER AÑO
DERMATOLOGÍA Y CIRUGÍA DERMATOLÓGICA
UNIVERSIDAD DEL VALLE
2017

CONTENIDO

DEFINICIÓN



Lee D, kolbinger F. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Clinical and epidemiological research. 2012:10:(1136)4

HISTORIA



Gaffen S et al. The IL-23 – iL-17 immune axis: from mechanisms to therapeutic testing. Nature Rev Immunol. 2014:14:586

CÉLULAS QUE SECRETAN IL-17





Jones S. Sutton C. Cua D. Therapeutic potential of targeting IL-17.Nature inmunology. 2012:13(11)254

DIFERENCIACIÓN INICIAL



Zúñiga L y col. Th17 cell development: from the cradle to the grave. Immunol Review. 2013: 252: 78-88.

ACTIVACIÓN



Zuñiga L. Et al. Th17 cell development: from the cradle to the grave. Immunol Review. 2013; 252:78-88.

Resolución de la inflamación



Zuñiga L. Et al. Th17 cell development: from the cradle to the grave. Immunol Review. 2013; 252:78-88.

DIFERENCIACIÓN



Kleinewietfeld M. Et al. The plasticity of human Treg and Th17 cells and its role in autoimmunity, Seminars in Immunology 2013:(15)305–312



Abbas et. al: Cellular and molecular inmunology 7e 2015.

IL-22 /IL-17 EN LA INMUNIDAD DE BARRERA



Sonnenberg G. Et al. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nature Immunology. 2011:12 (5): 383–390

CITOQUINAS SECRETADAS



Annunziato F. et al. Defining the human T helper 17 cell phenotype. Trends in Immunology. 2012: 33 (10) 506.

MIGRACIÓN DE LINFOCITOS Th-17 A MUCOSA INTESTINAL



Annunziato F. et al. Defining the human T helper 17 cell phenotype. Trends in Immunology. 2012: 33 (10) 506.

EFECTOS BIOLÓGICOS DE IL-17



Miossec P. Et al. Interleukin-17 and type 17 helper T cells. *The* new england journal *of* medicine. 2009;366:888–98



Th-17 y PSORIASIS

PSORIASIS

- Enfermedad inflamatoria autoinmune
- Individuos genéticamente susceptibles
- Placas inflamatorias

Schön M. Et al. Psoriasis. The lancet. 2015: 6736: (14) 61909-7

EJE IL-23/Th-17



Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105 (1): 9–20

FISIOPATOLOGIA



Presentación de Ag

Propagación de epítopes

Relocalización y reconocimiento cruzado

Reclutamiento - Establecimiento inflamat.

Diani.M. Et al. T cell responses in psoriasis and psoriatic arthritis. Autoimmunity Reviews. 2014:11:1-15

TRIÁNGULO INFLAMATORIO



Grine L. Et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Elsevier. 2014:10: 1359-6101

TERAPIA BIOLÓGICA EN PSORIASIS

TERAPIA BIOLÓGICA

- SECUKINUMAB
- IXEKIZUMAB
- BRODALUMAB



Wasilewska A. Et al. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Advances in Dermatology and Allergology. 2016; XXXIII (4): 247–252

MAS ALLÁ DE LA PSORIASIS…



Wasilewska A. Et al. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Advances in Dermatology and Allergology. 2016; XXXIII (4): 247–252

CONCLUSIONES

- LTCD4+Th17 juega un papel importante en la eliminación de patógenos extracelulares como bacterias y hongos
- LTCD4+ Th17 como célula clave en los procesos autoinmunitarios inflamatorios
- Hay nuevas alternativas en el tratamiento de la psoriasis con la terapia biologica dirigida a IL-17

¡Gracias!